Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
600329.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.41B
Close$
Share Statistics
| Market cap | $20.41 Billion |
|---|---|
| Enterprise Value | $18.22 Billion |
| Dividend Yield | $4.79 (13.38%) |
| Earnings per Share | $2.77 |
| Beta | 0.52 |
| Outstanding Shares | 770,094,356 |
Return
| Return on Equity | 14.26% |
|---|---|
| Return on Assets | 8.04% |
| Return on Invested Capital | 15.88% |
Valuation & Multiples
| P/E Ratio | 32.47 |
|---|---|
| PEG | -37.84 |
| Price to Sales | 5.97 |
| Price to Book Ratio | 5.11 |
| Enterprise Value to Revenue | 3.87 |
| Enterprise Value to EBIT | 19.04 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
October 23, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.69 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
3,890 employees
CEO: Lei Wang Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, along with its subsidiaries, primarily manufactures and markets traditional Chinese medicine, Western pharmaceuticals, and various healthcare products within the People's Repu...